Get the Stockscreener App
0.122
7.22%
-0.0095
Pre-market:
.12
-0.002
-1.64%
Aditxt Inc stock is traded at $0.122, with a volume of 18.23M.
It is down -7.22% in the last 24 hours and down -34.44% over the past month.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.
See More
Previous Close:
$0.1315
Open:
$0.1236
24h Volume:
18.23M
Relative Volume:
1.34
Market Cap:
$1.74M
Revenue:
$212.10K
Net Income/Loss:
$-40.19M
P/E Ratio:
-0.000023
EPS:
-5313.2836
Net Cash Flow:
$-13.92M
1W Performance:
-9.70%
1M Performance:
-34.44%
6M Performance:
-99.81%
1Y Performance:
-99.92%
1-Day Range:
$0.115
$0.1249
1-Week Range:
$0.115
$0.2077
52-Week Range:
$0.115
$218.00
Aditxt Inc Stock (ADTX) Company Profile
Name
Aditxt Inc
Sector
Industry
Phone
909-488-0844
Address
737 N. FIFTH STREET, SUITE 200, RICHMOND
Compare ADTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADTX
Aditxt Inc
|
0.122 | 1.74M | 212.10K | -40.19M | -13.92M | -5,313.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aditxt Inc Stock (ADTX) Latest News
Aditx Therapeutics stock hits 52-week low at $0.12 - Investing.com
Aditxt (NASDAQ: ADTX) Board Considers IPO for Subsidiary PearsantaMountain View, CA – January 13, 2025 – Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”) announced today that its Board of Directors has given the green light for exploring the p - Defense World
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Aditxt explores IPO for subsidiary Pearsanta in 2025 By Investing.com - Investing.com Canada
Aditxt explores IPO for subsidiary Pearsanta in 2025 - Investing.com India
Aditxt, Inc. Plans IPO for Pearsanta in 2025 - TipRanks
Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform - Quantisnow
Aditx Therapeutics stock hits 52-week low at $0.17 By Investing.com - Investing.com Australia
Aditx Therapeutics stock hits 52-week low at $0.17 - Investing.com
Shares Of Aditxt Inc (NASDAQ: ADTX): Are They Overvalued Compared To Others? - Stocks Register
Aditxt Inc (NASDAQ: ADTX) Inclines 3.78%: This $2.72 million Stock Could Go Down -79900.0% - Stocks Register
Perspective Therapeutics Inc (AMEX: CATX) Could Fell Another -684.31% - Stocks Register
Devon Energy Corp (NYSE: DVN) Stock Forecast: Could Pass $55 In A Year - Stocks Register
No Stopping Energy Transfer LP (NYSE: ET)’s Stock Surged? - Stocks Register
Aditxt, Inc. (NASDAQ:ADTX) Short Interest Down 45.2% in December - Defense World
ADTX stock plunges to 52-week low, touches $0.18 By Investing.com - Investing.com Nigeria
ADTX stock plunges to 52-week low, touches $0.18 - Investing.com
Aditx Therapeutics stock hits 52-week low at $0.31 By Investing.com - Investing.com Canada
Aditx Therapeutics stock hits 52-week low at $0.31 - Investing.com
Aditxt, Inc. (NASDAQ:ADTX) Sees Large Decrease in Short Interest - Defense World
Aditxt Advances ADI-100 Therapy to Human Trials - TipRanks
Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials - Quantisnow
Leslies Inc (LESL) Is Worth A Look Now, Despite -69.79% Loss From High - Stocks Register
Evofem Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits - Quantisnow
Evofem Biosciences Announces Financial Results for the Third Qua - GuruFocus.com
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 - Marketscreener.com
Aditxt extends merger agreement end date to January 2025 - Investing.com
Aditxt extends merger agreement end date to January 2025 By Investing.com - Investing.com UK
Appili Therapeutics Moves Forward with Aditxt Acquisition - TipRanks
Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc. - The Manila Times
Evofem Secures Investor Support for Proposed Merger through Voti - GuruFocus.com
Aditxt Inc. (ADTX) Quarterly 10-Q Report - Quartz
Aditxt, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ADTX stock plunges to 52-week low of $0.32 amid market challenges - Investing.com Canada
Evofem Cuts Q3 Operating Loss 31%, Acquires SOLOSEC Rights Despite Sales Dip | ADTX Stock News - StockTitan
Enviri Corp (NYSE: NVRI): Blank Check On Growth? - Stocks Register
Appili Therapeutics shareholders vote in favor of Aditxt transaction - TipRanks
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025 - The Manila Times
Aditxt, Inc. (NASDAQ:ADTX) Short Interest Update - Defense World
Aditxt suspends equity financing amid acquisition strategy - Investing.com
Aditxt suspends equity financing amid acquisition strategy By Investing.com - Investing.com UK
ADTX stock plunges to 52-week low, touches $0.42 - Investing.com India
ADTX stock plunges to 52-week low, touches $0.42 By Investing.com - Investing.com UK
Aditxt Secures Overwhelming Shareholder Approval for Appili Therapeutics Acquisition | ADTX Stock News - StockTitan
Appili Shareholders Approve Acquisition by Aditxt - TipRanks
Appili Therapeutics Announces Results of Special Meeting of Shareholders - Financial Post
Appili Therapeutics Announces Results of Special Meeting of Shareholders - GlobeNewswire Inc.
Aditxt announces Evofem secures voting agreements with investors for merger - TipRanks
Evofem Biosciences Gains Support for Aditxt Merger - TipRanks
Aditxt Inc Stock (ADTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):